PrEP Descovy Oral denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for prep descovy oral are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Prior Authorization for Descovy for PrEP — and How to Navigate It

UnitedHealthcare requires prior authorization (PA) for Descovy (emtricitabine/tenofovir alafenamide) as PrEP, meaning the plan must approve the prescription before the pharmacy will dispense it at the covered cost. A prior-auth denial — or a failure to obtain PA before dispensing — is not a final clinical determination; it is the start of a process. Understanding how to build a strong PA request, and how to appeal a PA denial, is the fastest path to access.

### Why This Is Appealable

If UHC denies the prior authorization, you have full appeal rights. The ACA's preventive-services mandate may also be relevant: for plans subject to the mandate, requiring prior authorization as a barrier to accessing a USPSTF Grade A-recommended preventive service like PrEP has been challenged in federal litigation as impermissible cost-sharing. Consult your state insurance commissioner or a patient advocate if this argument applies to your plan type.

### Your Federal Appeal Rights

• Internal appeal: Under ERISA §503 (employer plans) or ACA §2719 (individual/marketplace plans), a PA denial triggers full internal appeal rights. File within the deadline on your denial notice.
• External review: After a final internal denial, request IRO review within approximately four months under ACA §2719.
• Expedited review: If delay would seriously jeopardize your health, expedited review is typically decided within 72 hours — critical for initiating PrEP without interruption.
• Urgent/concurrent care exception: If you are already on Descovy and the PA renewal is denied mid-therapy, you may have additional protections for continuity of care.

### Building the PA Request

A complete, well-structured PA request is the most efficient path to approval. Gather:

1. Prescriber letter of medical necessity — should confirm: HIV-negative status with recent test date; clinical basis for PrEP candidacy consistent with applicable guideline organization criteria (CDC, USPSTF); rationale for Descovy specifically (versus formulary alternatives, if applicable); and that the prescriber has reviewed the FDA label and the patient meets the approved indication. 2. Recent HIV-negative test documentation — required by the FDA label before initiating PrEP. 3. UHC's PA criteria for Descovy/PrEP — download from UHC's provider portal before submitting. Address every criterion listed. 4. Applicable guideline reference — reference the CDC or USPSTF PrEP guidance organization generically to anchor the clinical rationale.

### If the PA Is Denied

Request the complete denial reason in writing. UHC is required to state the specific criterion not met. Build the appeal around that gap: if the denial cites a missing lab result, provide it; if it cites insufficient risk documentation, provide a detailed prescriber letter addressing risk factors.

### Criteria-Mapping Structure

For both the PA request and any appeal, use a two-column format: UHC criterion | Supporting documentation. Submit this as the cover sheet. Clear, structured submissions reduce back-and-forth and speed approval timelines.

### Next Step

Obtain UHC's current PA criteria for Descovy before the prescriber submits the request. Many PA denials result from incomplete initial submissions rather than genuine clinical disagreement. If the PA is denied, file the internal appeal immediately — do not wait for the final determination letter to arrive by mail.